Product Details

Verclox-250 Capsules meet Indian Pharmacopoeia (IP) standards for the treatment of bacterial infections. Specifically, each capsule delivers Cloxacillin Sodium equivalent to 250mg Cloxacillin. As a result, it offers targeted antibacterial coverage against penicillinase-producing staphylococcal strains.

The capsules contain:

• Cloxacillin Sodium IP (equivalent to Cloxacillin 250mg) – A penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis. Consequently, it remains effective against Staphylococcus strains that produce beta-lactamase enzymes capable of inactivating standard penicillins.

Physicians prescribe Verclox-250 for the treatment of infections caused by penicillinase-producing staphylococci, including skin and soft tissue infections, and as part of combination therapy for more complex bacterial infections. In addition, its targeted spectrum makes it a reliable choice when staphylococcal resistance is suspected or confirmed. Because of this profile, Verclox-250 suits general practice, surgical, and hospital settings managing resistant staphylococcal infections.

Key Features:

• Overall, this IP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the oral capsule format supports easy, convenient dosing
• Furthermore, each capsule delivers precise, validated dosage accuracy at 250mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, blister packaging protects capsule integrity against light and moisture
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies